Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Swiss biotech BioVersys gets $235 million valuation after completing flotation

Published by Global Banking and Finance Review

Posted on February 6, 2025

Featured image for article about Headlines

ZURICH (Reuters) - Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).

Just over 2.2 million shares were placed by the Basel-based company in the all-primary offering at 36 francs per share, it said on Thursday.

Trading is due to start on Friday, with the stock expected to be included on the Swiss Performance Index on February 10.

BioVersys researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.

It raised 90 million francs from the IPO, which will used towards the development of its BV100 treatment for infections linked to ventilator-associated pneumonia and bloodstream infections.

Some of the money will be used for its tuberculosis product alpibectir, which BioVersys is working on with GSK.

CEO Marc Gitzinger said the IPO was the next stage in the company's growth strategy.

"This support enables us to move full speed ahead with BV100 into the Phase 3 program, advance alpibectir into additional Phase 2 trials in collaboration with GSK and further progress our early stage pipeline," he said.

($1 = 0.9046 Swiss francs)

(Reporting by John Revill; Editing by Bernadette Baum)